Overview

Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study will be undertaken to evaluate the feasibility of replacing systemic Androgen Deprivation Therapy (ADT) with targeted local delivery of an anti-androgen agent alone in patients in whom ADT + radiation therapy is indicated for the treatment of localized prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Alessa Therapeutics Inc.
Collaborator:
National Cancer Institute (NCI)
Treatments:
Bicalutamide